Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q5T890
UPID:
ER6L2_HUMAN
Alternative names:
DNA repair and recombination protein RAD26-like
Alternative UPACC:
Q5T890; A4D997; B2RTP8; Q49AM9; Q5T892; Q8N663; Q8N9D0; Q9NPM7
Background:
The DNA excision repair protein ERCC-6-like 2, also known as DNA repair and recombination protein RAD26-like, plays a crucial role in the DNA damage response. Its involvement in early DNA damage response mechanisms underscores its importance in maintaining genomic integrity and preventing mutations.
Therapeutic significance:
Linked to Bone marrow failure syndrome 2, a disorder characterized by bone marrow failure and learning difficulties, this protein's dysfunction highlights its potential as a target for therapeutic intervention. Understanding the role of DNA excision repair protein ERCC-6-like 2 could open doors to potential therapeutic strategies.